Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 48.7x - 53.9x | 51.3x |
| Historical Pb Multiple | 10.0x - 82.8x | 20.2x |
| Fair Value | $8.70 - $9.62 | $9.16 |
| Upside | -47.1% - -41.5% | -44.3% |
| Benchmarks | - | Full Ticker |
| International Stem Cell Corporation | - | OTCPK:ISCO |
| Lineage Cell Therapeutics, Inc. | - | NYSEAM:LCTX |
| Cuorips Inc. | 489,400.0% | TSE:4894 |
| Oncolys BioPharma Inc. | 458,800.0% | TSE:4588 |
| CanBas Co., Ltd. | 457,500.0% | TSE:4575 |
| SanBio Company Limited | - | OTCPK:SNBI.F |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| ISCO | LCTX | 4894 | 4588 | 4575 | SNBI.F | |||
| OTCPK:ISCO | NYSEAM:LCTX | TSE:4894 | TSE:4588 | TSE:4575 | OTCPK:SNBI.F | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 48.4% | -69.1% | NM | -22.9% | 4.3% | -97.5% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | -12.4% | -447.6% | -1385.8% | -2322.5% | -954.0% | -30394.3% | ||
| Prior Fiscal Year | -1.7% | -240.2% | -2747.8% | -3075.1% | NA | NA | ||
| Latest Fiscal Year | -2.3% | -195.9% | -368.0% | -5368.3% | NA | NA | ||
| Latest Twelve Months | -2.6% | -169.6% | -368.0% | -7858.0% | NA | NA | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | NA | -32.0% | -7.8% | -77.4% | -142.9% | -115.3% | ||
| Prior Fiscal Year | NM | -31.4% | -10.6% | -106.7% | -56.6% | -73.2% | ||
| Latest Twelve Months | NM | -70.1% | -11.6% | -157.1% | -43.8% | -198.9% | ||
| Next Fiscal Year | 5.1% | -39.2% | -71.5% | #NUM! | #NUM! | 3620.7% | ||
| Two Fiscal Years Forward | -3.6% | -41.7% | -373.9% | -88.6% | #NUM! | 62.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.1x | 24.9x | 224.3x | 637.2x | NA | NA | ||
| Price / LTM EPS | -5.4x | -6.6x | -89.4x | -8.1x | -17.2x | -43.4x | ||
| Price / Book | -0.3x | 5.6x | 10.8x | 12.6x | 6.8x | 97.9x | ||
| Price / Fwd Book | -0.3x | 5.2x | 22.3x | 6.6x | 6.8x | -88.7x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | -0.3x | 6.8x | 12.6x | |||||
| Historical P/B Ratio | 10.0x | 20.2x | 82.8x | |||||
| Selected P/B Multiple | 48.7x | 51.3x | 53.9x | |||||
| (x) Book Value | 1,895 | 1,895 | 1,895 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | ISCO | LCTX | 4894 | 4588 | 4575 | SNBI.F | |
| Value of Common Equity | 1 | 272 | 58,308 | 18,188 | 19,916 | 174,551 | |
| (/) Shares Outstanding | 8.0 | 228.4 | 8.1 | 24.8 | 19.1 | 72.0 | |
| Implied Stock Price | 0.16 | 1.19 | 7,200.00 | 732.00 | 1,042.00 | 2,423.82 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 147.34 | |
| Implied Stock Price (Trading Cur) | 0.16 | 1.19 | 7,200.00 | 732.00 | 1,042.00 | 16.45 | |
| Trading Currency | USD | USD | JPY | JPY | JPY | USD | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 147.34 | |